Eruption column height estimation of the 2011-2013 Etna lava fountains

In this paper, we use calibrated images collected by the video-surveillance system of the Istituto Nazionale di Geofisica e Vulcanologia, Osservatorio Etneo, to retrieve the height of the eruption column during the recent Etna explosive activity. The analysis is carried out on nineteen lava fountains from the New South East Crater dataset. The novel procedure described in this work is achieved in three main steps: at first we calibrated the camera, then we selected the images which recorded the maximum phase of the eruptive activity, and finally we applied an appropriate correction to account for the plume projection on the camera line of sight due to the wind. The results show that the column altitudes range between 6 and 9 km (upper limit of the camera system). The comparison with the plume height values estimated from the analysis of several SEVIRI and MODIS satellite images, show a good agreement. Finally, for nine events we also evaluated the thickness of the volcanic plumes in the umbrella region which ranges between 2 and 3 km

Eruption column height estimation of the 2011-2013 Etna lava fountains

In this paper, we use calibrated images collected by the video-surveillance system of the Istituto Nazionale di Geofisica e Vulcanologia, Osservatorio Etneo, to retrieve the height of the eruption column during the recent Etna explosive activity. The analysis is carried out on nineteen lava fountains from the New South East Crater dataset. The novel procedure described in this work is achieved in three main steps: at first we calibrated the camera, then we selected the images which recorded the maximum phase of the eruptive activity, and finally we applied an appropriate correction to account for the plume projection on the camera line of sight due to the wind. The results show that the column altitudes range between 6 and 9 km (upper limit of the camera system). The comparison with the plume height values estimated from the analysis of several SEVIRI and MODIS satellite images, show a good agreement. Finally, for nine events we also evaluated the thickness of the volcanic plumes in the umbrella region which ranges between 2 and 3 km

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials

Background: Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data from all relevant unconfounded randomised trials of gastroprotectant drugs. Background: Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data from all relevant unconfounded randomised trials of gastroprotectant drugs. Methods: We searched MEDLINE and Embase from Jan 1, 1950, to Dec 31, 2015, to identify unconfounded, randomised trials of a gastroprotectant drug (defined as a PPI, prostaglandin analogue, or H2RA) versus control, or versus another gastroprotectant. Two independent researchers reviewed the search results and extracted the prespecified outcomes and key characteristics for each trial. We did meta-analyses of the effects of gastroprotectant drugs on ulcer development, bleeding, and mortality overall, according to the class of gastroprotectant, and according to the individual drug within a gastroprotectant class. Findings: We identified comparisons of gastroprotectant versus control in 849 trials (142 485 participants): 580 prevention trials (110 626 participants), 233 healing trials (24 033 participants), and 36 trials for the treatment of acute upper gastrointestinal bleeding (7826 participants). Comparisons of one gastroprotectant drug versus another were available in 345 trials (64 905 participants), comprising 160 prevention trials (32 959 participants), 167 healing trials (28 306 participants), and 18 trials for treatment of acute upper gastrointestinal bleeding (3640 participants). The median number of patients in each trial was 78 (IQR 44·0–210·5) and the median duration was 1·4 months (0·9–2·8). In prevention trials, gastroprotectant drugs reduced development of endoscopic ulcers (odds ratio [OR] 0·27, 95% CI 0·25–0·29; p<0·0001), symptomatic ulcers (0·25, 0·22–0·29; p<0·0001), and upper gastrointestinal bleeding (0·40, 0·32–0·50; p<0·0001), but did not significantly reduce mortality (0·85, 0·69–1·04; p=0·11). Larger proportional reductions in upper gastrointestinal bleeding were observed for PPIs than for other gastroprotectant drugs (PPIs 0·21, 99% CI 0·12–0·36; prostaglandin analogues 0·63, 0·35–1·12; H2RAs 0·49, 0·30–0·80; phet=0·0005). Gastroprotectant drugs were effective in preventing bleeding irrespective of the use of non-steroidal anti-inflammatory drugs (phet=0·56). In healing trials, gastroprotectants increased endoscopic ulcer healing (3·49, 95% CI 3·28–3·72; p<0·0001), with PPIs more effective (5·22, 99% CI 4·00–6·80) than prostaglandin analogues (2·27, 1·91–2·70) and H2RAs (3·80, 3·44–4·20; phet<0·0001). In trials among patients with acute bleeding, gastroprotectants reduced further bleeding (OR 0·68, 95% CI 0·60–0·78; p<0·0001), blood transfusion (0·75, 0·65–0·88; p=0·0003), further endoscopic intervention (0·56, 0·45–0·70; p<0·0001), and surgery (0·72, 0·61–0·84; p<0·0001), but did not significantly reduce mortality (OR 0·90, 0·72–1·11; p=0·31). PPIs had larger protective effects than did H2RAs for further bleeding (phet=0·0107) and blood transfusion (phet=0·0130). Interpretation: Gastroprotectants, in particular PPIs, reduce the risk of peptic ulcer disease and its complications and promote healing of peptic ulcers in a wide range of clinical circumstances. However, this meta-analysis might have overestimated the benefits owing to small study bias

Improvement of ash plume monitoring, modeling and hazard assessment in the MED-SUV project

Volcanic ash clouds produced by explosive eruptions represent a strong problem for civil aviation, road transportation and other human activities. Since Etna volcano produced in the last 35 years more the 200 explosive eruptions of small and medium size. The INGV, liable for its volcano monitoring, developed since 2006 a specific system for forecasting and monitoring Etna’s volcanic ash plumes in collaboration with several national and international institutions. Between 12 January 2011 and 31 December 2013 Etna produced forty-six basaltic lava fountains. Every paroxysm produced an eruption column ranging from a few up to eleven kilometers of height above sea level. The ash cloud contaminated the controlled airspace (CTR) of Catania and Reggio Calabria airports and caused tephra fallout on eastern Sicily sometime disrupting the operations of these airports. In order to give prompt and detailed warnings to the Aviation and Civil Protection authorities, ash plumes monitoring at Osservatorio Etneo, the INGV department in Catania, is carried out using multispectral (from visible to infrared) satellite and ground-based video-surveillance images; seismic and infrasound signals processed in real-time, a Doppler RADAR (Voldorad IIB) able to detect the eruption column in all weather conditions and a LIDAR (AMPLE) for retrieving backscattering and depolarization values of the ash clouds. Forecasting is performed running tephra dispersal models using weather forecast data, and then plotting results on maps published on a dedicated website. 24/7 Control Room operators were able to timely nform Aviation and Civil Protection operators for an effective aviation safety management. A variety of multidisciplinary activities are planned in the MED-SUV project with reference to volcanic ash observations and studies. These include: 1) physical and analogue laboratory experiments on ash dispersal and aggregation; 2) integration of satellite data (e.g. METEOSAT, MODIS) and ground- based measurements (e.g., RADAR, LIDAR) of Etna’s volcanic plumes to quantify mass eruption rate, grain-size distribution at source, and ash cloud concentration; 3) improvement of tools and automatic procedures for the short-term forecasting of volcanic ash dispersal by adopting a multi-model and multi-scenario approach; 4) development of short-term forecasting tools able to use direct measurements of the plume and ash cloud in almost real time (now-casting); 5) development of long-term probabilistic ash fallout maps at the supersite volcanoes.PublishedVienna, Austria4V. Vulcani e ambienteope

Improvement of ash plume monitoring, modeling and hazard assessment in the MED-SUV project

Volcanic ash clouds produced by explosive eruptions represent a strong problem for civil aviation, road transportation and other human activities. Since Etna volcano produced in the last 35 years more the 200 explosive eruptions of small and medium size. The INGV, liable for its volcano monitoring, developed since 2006 a specific system for forecasting and monitoring Etna’s volcanic ash plumes in collaboration with several national and international institutions. Between 12 January 2011 and 31 December 2013 Etna produced forty-six basaltic lava fountains. Every paroxysm produced an eruption column ranging from a few up to eleven kilometers of height above sea level. The ash cloud contaminated the controlled airspace (CTR) of Catania and Reggio Calabria airports and caused tephra fallout on eastern Sicily sometime disrupting the operations of these airports. In order to give prompt and detailed warnings to the Aviation and Civil Protection authorities, ash plumes monitoring at Osservatorio Etneo, the INGV department in Catania, is carried out using multispectral (from visible to infrared) satellite and ground-based video-surveillance images; seismic and infrasound signals processed in real-time, a Doppler RADAR (Voldorad IIB) able to detect the eruption column in all weather conditions and a LIDAR (AMPLE) for retrieving backscattering and depolarization values of the ash clouds. Forecasting is performed running tephra dispersal models using weather forecast data, and then plotting results on maps published on a dedicated website. 24/7 Control Room operators were able to timely nform Aviation and Civil Protection operators for an effective aviation safety management. A variety of multidisciplinary activities are planned in the MED-SUV project with reference to volcanic ash observations and studies. These include: 1) physical and analogue laboratory experiments on ash dispersal and aggregation; 2) integration of satellite data (e.g. METEOSAT, MODIS) and ground- based measurements (e.g., RADAR, LIDAR) of Etna’s volcanic plumes to quantify mass eruption rate, grain-size distribution at source, and ash cloud concentration; 3) improvement of tools and automatic procedures for the short-term forecasting of volcanic ash dispersal by adopting a multi-model and multi-scenario approach; 4) development of short-term forecasting tools able to use direct measurements of the plume and ash cloud in almost real time (now-casting); 5) development of long-term probabilistic ash fallout maps at the supersite volcanoes

ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

OBJECTIVES: This collaborative study, based on data collected by the network of Italian Cancer Registries (AIRTUM), describes the burden of rare cancers in Italy. Estimated number of new rare cancer cases yearly diagnosed (incidence), proportion of patients alive after diagnosis (survival), and estimated number of people still alive after a new cancer diagnosis (prevalence) are provided for about 200 different cancer entities. MATERIALS AND METHODS: Data herein presented were provided by AIRTUM population- based cancer registries (CRs), covering nowadays 52% of the Italian population. This monograph uses the AIRTUM database (January 2015), which includes all malignant cancer cases diagnosed between 1976 and 2010. All cases are coded according to the International Classification of Diseases for Oncology (ICD-O-3). Data underwent standard quality checks (described in the AIRTUM data management protocol) and were checked against rare-cancer specific quality indicators proposed and published by RARECARE and HAEMACARE (www.rarecarenet.eu; www.haemacare.eu). The definition and list of rare cancers proposed by the RARECAREnet "Information Network on Rare Cancers" project were adopted: rare cancers are entities (defined as a combination of topographical and morphological codes of the ICD-O-3) having an incidence rate of less than 6 per 100,000 per year in the European population. This monograph presents 198 rare cancers grouped in 14 major groups. Crude incidence rates were estimated as the number of all new cancers occurring in 2000-2010 divided by the overall population at risk, for males and females (also for gender-specific tumours).The proportion of rare cancers out of the total cancers (rare and common) by site was also calculated. Incidence rates by sex and age are reported. The expected number of new cases in 2015 in Italy was estimated assuming the incidence in Italy to be the same as in the AIRTUM area. One- and 5-year relative survival estimates of cases aged 0-99 years diagnosed between 2000 and 2008 in the AIRTUM database, and followed up to 31 December 2009, were calculated using complete cohort survival analysis. To estimate the observed prevalence in Italy, incidence and follow-up data from 11 CRs for the period 1992-2006 were used, with a prevalence index date of 1 January 2007. Observed prevalence in the general population was disentangled by time prior to the reference date (≤2 years, 2-5 years, ≤15 years). To calculate the complete prevalence proportion at 1 January 2007 in Italy, the 15-year observed prevalence was corrected by the completeness index, in order to account for those cancer survivors diagnosed before the cancer registry activity started. The completeness index by cancer and age was obtained by means of statistical regression models, using incidence and survival data available in the European RARECAREnet data. RESULTS: In total, 339,403 tumours were included in the incidence analysis. The annual incidence rate (IR) of all 198 rare cancers in the period 2000-2010 was 147 per 100,000 per year, corresponding to about 89,000 new diagnoses in Italy each year, accounting for 25% of all cancer. Five cancers, rare at European level, were not rare in Italy because their IR was higher than 6 per 100,000; these tumours were: diffuse large B-cell lymphoma and squamous cell carcinoma of larynx (whose IRs in Italy were 7 per 100,000), multiple myeloma (IR: 8 per 100,000), hepatocellular carcinoma (IR: 9 per 100,000) and carcinoma of thyroid gland (IR: 14 per 100,000). Among the remaining 193 rare cancers, more than two thirds (No. 139) had an annual IR <0.5 per 100,000, accounting for about 7,100 new cancers cases; for 25 cancer types, the IR ranged between 0.5 and 1 per 100,000, accounting for about 10,000 new diagnoses; while for 29 cancer types the IR was between 1 and 6 per 100,000, accounting for about 41,000 new cancer cases. Among all rare cancers diagnosed in Italy, 7% were rare haematological diseases (IR: 41 per 100,000), 18% were solid rare cancers. Among the latter, the rare epithelial tumours of the digestive system were the most common (23%, IR: 26 per 100,000), followed by epithelial tumours of head and neck (17%, IR: 19) and rare cancers of the female genital system (17%, IR: 17), endocrine tumours (13% including thyroid carcinomas and less than 1% with an IR of 0.4 excluding thyroid carcinomas), sarcomas (8%, IR: 9 per 100,000), central nervous system tumours and rare epithelial tumours of the thoracic cavity (5%with an IR equal to 6 and 5 per 100,000, respectively). The remaining (rare male genital tumours, IR: 4 per 100,000; tumours of eye, IR: 0.7 per 100,000; neuroendocrine tumours, IR: 4 per 100,000; embryonal tumours, IR: 0.4 per 100,000; rare skin tumours and malignant melanoma of mucosae, IR: 0.8 per 100,000) each constituted <4% of all solid rare cancers. Patients with rare cancers were on average younger than those with common cancers. Essentially, all childhood cancers were rare, while after age 40 years, the common cancers (breast, prostate, colon, rectum, and lung) became increasingly more frequent. For 254,821 rare cancers diagnosed in 2000-2008, 5-year RS was on average 55%, lower than the corresponding figures for patients with common cancers (68%). RS was lower for rare cancers than for common cancers at 1 year and continued to diverge up to 3 years, while the gap remained constant from 3 to 5 years after diagnosis. For rare and common cancers, survival decreased with increasing age. Five-year RS was similar and high for both rare and common cancers up to 54 years; it decreased with age, especially after 54 years, with the elderly (75+ years) having a 37% and 20% lower survival than those aged 55-64 years for rare and common cancers, respectively. We estimated that about 900,000 people were alive in Italy with a previous diagnosis of a rare cancer in 2010 (prevalence). The highest prevalence was observed for rare haematological diseases (278 per 100,000) and rare tumours of the female genital system (265 per 100,000). Very low prevalence (<10 prt 100,000) was observed for rare epithelial skin cancers, for rare epithelial tumours of the digestive system and rare epithelial tumours of the thoracic cavity. COMMENTS: One in four cancers cases diagnosed in Italy is a rare cancer, in agreement with estimates of 24% calculated in Europe overall. In Italy, the group of all rare cancers combined, include 5 cancer types with an IR>6 per 100,000 in Italy, in particular thyroid cancer (IR: 14 per 100,000).The exclusion of thyroid carcinoma from rare cancers reduces the proportion of them in Italy in 2010 to 22%. Differences in incidence across population can be due to the different distribution of risk factors (whether environmental, lifestyle, occupational, or genetic), heterogeneous diagnostic intensity activity, as well as different diagnostic capacity; moreover heterogeneity in accuracy of registration may determine some minor differences in the account of rare cancers. Rare cancers had worse prognosis than common cancers at 1, 3, and 5 years from diagnosis. Differences between rare and common cancers were small 1 year after diagnosis, but survival for rare cancers declined more markedly thereafter, consistent with the idea that treatments for rare cancers are less effective than those for common cancers. However, differences in stage at diagnosis could not be excluded, as 1- and 3-year RS for rare cancers was lower than the corresponding figures for common cancers. Moreover, rare cancers include many cancer entities with a bad prognosis (5-year RS <50%): cancer of head and neck, oesophagus, small intestine, ovary, brain, biliary tract, liver, pleura, multiple myeloma, acute myeloid and lymphatic leukaemia; in contrast, most common cancer cases are breast, prostate, and colorectal cancers, which have a good prognosis. The high prevalence observed for rare haematological diseases and rare tumours of the female genital system is due to their high incidence (the majority of haematological diseases are rare and gynaecological cancers added up to fairly high incidence rates) and relatively good prognosis. The low prevalence of rare epithelial tumours of the digestive system was due to the low survival rates of the majority of tumours included in this group (oesophagus, stomach, small intestine, pancreas, and liver), regardless of the high incidence rate of rare epithelial cancers of these sites. This AIRTUM study confirms that rare cancers are a major public health problem in Italy and provides quantitative estimations, for the first time in Italy, to a problem long known to exist. This monograph provides detailed epidemiologic indicators for almost 200 rare cancers, the majority of which (72%) are very rare (IR<0.5 per 100,000). These data are of major interest for different stakeholders. Health care planners can find useful information herein to properly plan and think of how to reorganise health care services. Researchers now have numbers to design clinical trials considering alternative study designs and statistical approaches. Population-based cancer registries with good quality data are the best source of information to describe the rare cancer burden in a population